MarketCap
Facebook
X
Telegram
Blueprint Medicines Corporation Revenue | BPMC
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Blueprint Medicines Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 509 M | 249 M | 204 M | 180 M | 794 M | 66.5 M | 44.5 M | 21.4 M | 27.8 M | 11.4 M | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 794 M | 11.4 M | 211 M |
Quarterly Revenue Blueprint Medicines Corporation
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 149 M | - | 128 M | 138 M | 96.1 M | - | 56.6 M | 57.6 M | 63.3 M | - | 66 M | 36.5 M | 62.7 M | - | 24.2 M | 27.3 M | 21.6 M | - | 745 M | 8.34 M | 6.17 M | 51.5 M | 9.14 M | 5.11 M | 730 K | 1.03 M | 1.1 M | 41.4 M | 954 K | 1.63 M | 8.07 M | 5.89 M | 5.84 M | 7.69 M | 6.16 M | 7.06 M | 6.86 M | 4.64 M | 3.43 M | 2.69 M | 652 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 745 M | 652 K | 51.6 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
12 B | $ 523.93 | -2.1 % | $ 134 B |  USA |
 |
Abeona Therapeutics
ABEO
|
5.82 M | $ 4.4 | -1.57 % | $ 233 M | USA |
 |
AbbVie
ABBV
|
16.6 B | $ 285.64 | 0.24 % | $ 505 B | USA |
 |
AIM ImmunoTech
AIM
|
88 K | $ 0.16 | -4.11 % | $ 259 K | USA |
 |
Akebia Therapeutics
AKBA
|
236 M | $ 0.57 | 0.84 % | $ 147 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
14.1 M | $ 4.2 | -0.24 % | $ 805 M |  Canada |
 |
ACADIA Pharmaceuticals
ACAD
|
1.07 B | $ 19.73 | -2.86 % | $ 3.32 B | USA |
 |
ADC Therapeutics SA
ADCT
|
81.4 M | $ 1.44 | -9.72 % | $ 183 M |  Schweiz |
 |
Adaptive Biotechnologies Corporation
ADPT
|
277 M | $ 25.51 | 4.51 % | $ 3.87 B | USA |
 |
EyePoint Pharmaceuticals
EYPT
|
31.4 M | $ 0.4 | -5.51 % | $ 29.3 K | USA |
 |
Seagen
SGEN
|
1.96 B | - | - | $ 42.2 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
54 M | $ 37.0 | -0.51 % | $ 2.14 B | USA |
 |
Oncternal Therapeutics
ONCT
|
785 K | - | -24.12 % | $ 1.56 M | USA |
 |
Iterum Therapeutics
ITRM
|
37 K | - | - | $ 591 K |  Irlanda |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
Achieve Life Sciences
ACHV
|
5.06 M | $ 6.49 | -0.15 % | $ 283 M | USA |
 |
Alpine Immune Sciences
ALPN
|
58.9 M | - | - | $ 2.17 B | USA |
 |
Geron Corporation
GERN
|
237 K | $ 1.12 | -0.88 % | $ 747 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
32.6 M | - | - | $ 401 M | USA |
 |
Gilead Sciences
GILD
|
29.4 B | $ 156.04 | -0.73 % | $ 194 B | USA |
 |
Genmab A/S
GMAB
|
10.1 B | $ 43.79 | 9.48 % | $ 2.83 B |  Danmark |
 |
Crinetics Pharmaceuticals
CRNX
|
7.7 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
ImmunoGen
IMGN
|
109 M | - | - | $ 7.92 B | USA |
 |
GeoVax Labs
GOVX
|
2.49 M | $ 0.21 | -3.15 % | $ 201 K | USA |
 |
GlaxoSmithKline plc
GSK
|
32.7 B | $ 50.75 | -0.9 % | $ 206 B |  Britain |
 |
GT Biopharma
GTBP
|
27 K | $ 5.46 | -1.09 % | $ 30.1 M | USA |
 |
Vascular Biogenics Ltd.
VBLT
|
310 K | - | -8.77 % | $ 12.4 M |  Israel |
 |
Amarin Corporation plc
AMRN
|
214 M | $ 11.79 | 1.64 % | $ 4.89 B | Irlanda |
 |
Berkeley Lights
BLI
|
78.6 M | - | -7.31 % | $ 87 M | USA |
 |
Histogen
HSTO
|
3.77 M | - | 31.6 % | $ 2.12 M | USA |
 |
Halozyme Therapeutics
HALO
|
1.4 B | $ 125.63 | 0.88 % | $ 15.1 B | USA |
 |
Cidara Therapeutics
CDTX
|
1.28 M | - | - | $ 1.41 B | USA |
 |
Hutchison China MediTech Limited
HCM
|
549 M | $ 14.36 | 0.56 % | $ 12.3 B |  China |
 |
AnaptysBio
ANAB
|
53 M | $ 48.73 | 1.31 % | $ 1.41 B | USA |
 |
Clovis Oncology
CLVS
|
36 M | - | -7.23 % | $ 13 M | USA |
 |
Harmony Biosciences Holdings
HRMY
|
868 M | $ 36.13 | 0.28 % | $ 2.08 B | USA |
 |
Anika Therapeutics
ANIK
|
113 M | $ 21.42 | 1.56 % | $ 307 M | USA |
 |
iBio
IBIO
|
100 K | $ 0.72 | -8.44 % | $ 74.9 M | USA |
 |
Axon Enterprise
AXON
|
2.78 B | $ 420.37 | 1.39 % | $ 32.8 B | USA |
 |
Immunome
IMNM
|
6.94 M | $ 17.99 | -1.48 % | $ 1.57 B | USA |
 |
Immuron Limited
IMRN
|
7.29 M | $ 0.95 | 0.44 % | $ 219 M |  Australia |
 |
InMed Pharmaceuticals
INM
|
4.94 M | $ 1.44 | 8.27 % | $ 6 M | Canada |
 |
Inovio Pharmaceuticals
INO
|
65.3 K | $ 0.9 | 6.94 % | $ 42.2 M | USA |
 |
Insmed Incorporated
INSM
|
606 M | $ 93.39 | -1.76 % | $ 18.6 B | USA |
 |
Akari Therapeutics, Plc
AKTX
|
368 K | $ 8.23 | 1.54 % | $ 554 B | Britain |
 |
Innoviva
INVA
|
411 M | $ 20.66 | -1.9 % | $ 1.39 B | USA |
 |
Ionis Pharmaceuticals
IONS
|
203 M | $ 42.93 | -2.23 % | $ 6.87 B | USA |